Gateway Immunization Coalition

"Lickety Split"

Update on Flu Vaccine

September 23rd, 2016

Saralou Hendrickson RN, MSN, MPH

Influenza/ Flu

- Highly infectious viral illness
- First pandemic in 1580
- At least 4 pandemics in 19th century
- Estimated 21 million deaths worldwide in pandemic of 1918-1919
- Virus first isolated in 1933

2009 Influenza A (H1N1)

- April 2009, novel influenza A (H1N1) appeared; spread across North America
- Cause of the first influenza pandemic since 1968
- Ninety percent of hospitalizations and deaths occurred in persons younger then 65 years of age
- Pandemic monovalent influenza vaccine produced and deployed nationwide

Influenza Virus

- Single-stranded RNA virus
- Orthomyxoviridae family
- ■3 types: A,B,C
- Subtypes of type A determined by hemagglutinin and neuraminidase

Influenza Virus Strains

Type A-moderate to severe illness

- -all age groups
- humans and other animals

Type B-milder disease

- primarily affects children
- humans only

Type C-rarely reported in humans

no epidemics

Influenza Pathogenesis

- Respiratory transmission of virus
- Replication in respiratory epithelium with subsequent destruction of cells
- Viremia rarely documented
- Virus shed in respiratory secretions for 5-10 days

Influenza Clinical Features

- Incubation period 2 days (range 1-4 days)
- 50% of infected persons develop classic symptoms
- Abrupt onset of fever, myalgia, sore throat, nonproductive cough, headache

Influenza Complications

- Pneumonia
 - Secondary bacterial
 - Primary influenza viral
- Reye syndrome
- Myocarditis
- Death is reported than less than 1 per 1,000 cases

Impact of Influenza - United States, 1976-2007

- The number of influenza-associated deaths varies substantially by year, influenza virus type and subtype, and age group
- Annual influenza-associated deaths ranged from 3,349 (1985-86 season) to 48,614 (2003-04 season), with an average of 23,607 annual deaths
- Persons 65 years of age and older account for approximately 90% of deaths
- 2.7 times more deaths occurred during seasons when A(H3N2) viruses were prominent

Impact of Influenza - United States

- Highest rates of complications and hospitalization among persons \geq 65, young children, and persons of any age with certain underlying medical conditions
- Average of more than 200,000 influenza-related excess hospitalizations
- 37% of hospitalizations among persons younger than 65 years of age
- Greater number of hospitalizations during years that A(H3N2) is predominant

Influenza Among School-Aged Children

School-aged children

- Typically have the highest attack rates during community outbreaks of influenza
- Serve as a major source of transmission of influenza within communities

Influenza Diagnosis

- Clinical and epidemiological characteristics
- Isolation of influenza virus from clinical specimen (e.g., throat, nasopharynx, sputum)
- Significant rise in influenza IgG by serologic assay

Influenza Epidemiology

- Reservoir
 - -Human, animals (type A only)
- Transmission
 - -Respiratory
 - -probably airborne
- Temporal pattern
 - -peak December March in temperate climate
 - -may occur earlier or later
- Communicability
 - -1 day before to 5 days after onset (adults)

Influenza Vaccines

Inactivated (IIV) – Given intramuscularly Age requirements depend on brand

- Quadrivalent
- Cell-culture based quadrivalent
- Trivalent
- Adjuvanted trivalent- age 65 and over
- High-dose trivalent age 65 and over
- Recombinant trivalent age 18 and over
- Quadrivalant intradermal ages 18 through 64
- Live attenuated intranasal not recommended this year

Inactivated Influenza Vaccine Efficacy

- About 60% effective among healthy persons younger than 65 years of age
- 50-60% effective in preventing hospitalization among elderly persons
- 80% effective in preventing death among elderly persons

Pregnancy and Inactivated Influenza Vaccine

- Risk of hospitalization 4 times higher than nonpregnant women
- Risk of complications comparable to nonpregnant women with high-risk medical conditions
- Vaccination (with IIV) recommended if pregnant during influenza season
- Vaccination can occur during any trimester

Inactivated Influenza Vaccine Contraindications and Precautions

- Severe allergic reaction (e.g., anaphylaxis) to a vaccine component or following a prior dose of inactivated influenza
- Moderate or severe acute illness
- History of Guillian-Barré syndrome (GBS) within 6 weeks following a previous dose of influenza vaccine

Influenza Vaccine Adverse Events

IIV

- Local reactions common
- Guillain-Barré syndrome expected to be greater among persons with a history of GBS than among persons with no history of GBS

LAIV

Nonspecific systemic symptoms – common

Inactivated Influenza Vaccine Adverse Reactions

- Local reactions (soreness, redness) 15%-20%
- Fever, malaise, myalgia less than 1%
- Allergic reactions (hives, angioedema, anaphylaxis)
 rare

Source:

- The pink Book-last updated on September 8,2015. Centers for Disease Control and Prevention. Retrieved from: http://www.cdc.gov/vaccines/pubs/pinkbook/flu.html
- Prevention and Control of Seasonal Influenza with Vaccines Recommendations of the Advisory Committee on Immunization Practices United States, 2016-2017 Influenza Season